MetaCap

HUTCHMED (China) (HCM) vs Xencor (XNCR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xencor (XNCR) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 109.6% versus a loss of 5.6%. Over five years, XNCR leads with a -6.2% price change compared with -62.4% for HCM. Xencor is the larger company by market cap ($2.50 billion vs $2.30 billion), about 1.1 times the size.

HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus -73.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HCM-5.57%XNCR+109.58%
+161%+59%-44%
Nov 21, 20251 yearNov 20, 2026
HCM-56.97%XNCR-9.77%
+20%-33%-85%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HCM versus XNCR key metrics
MetricHCMXNCR
Share price$13.22$33.26
Market cap$2.30B$2.50B
1-day change-1.71%-2.21%
YTD return-0.83%+117.24%
1-year return-5.57%+109.58%
5-year return-62.42%-6.15%
P/E ratio (TTM)132.20—
Forward P/E51.00—
EPS (TTM)$0.10$-1.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$548.51M$125.58M
Revenue growth (YoY)-12.96%+13.65%
Net income (latest FY)$456.91M$-91.92M
Gross margin38.68%—
Operating margin-7.14%-141.35%
Net margin83.30%-73.20%
52-week high$16.33$40.60
52-week low$9.77$10.38
Distance from 52-week high-19.04%-18.08%
Analyst consensusnonestrong_buy
Avg. price target upside+59.91%+27.78%
Average volume64.48K1.54M
Shares outstanding173.81M75.04M
Employees1,790260
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XNCR has outperformed HCM by 115.1 percentage points over the past year.
  • HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus -73.2 cents for Xencor.
  • Xencor grew revenue faster in its latest fiscal year (+13.65% vs -12.96%).

About HUTCHMED (China)

HCM stock →

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees

About Xencor

XNCR stock →

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

HCM vs XNCR FAQ

Which is bigger, HUTCHMED (China) or Xencor?

Xencor (XNCR) is larger, with a market capitalization of $2.50B compared with $2.30B for HUTCHMED (China) (HCM).

Which stock has performed better over the past year, HCM or XNCR?

XNCR returned +109.58% over the past 12 months, compared with -5.57% for HCM (price return, excluding dividends). Past performance does not predict future results.

Are HUTCHMED (China) and Xencor in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons